Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit and Capitalization (Detail Textuals)

v3.19.2
Stockholders' Deficit and Capitalization (Detail Textuals) - USD ($)
 1 Months Ended 6 Months Ended
Feb. 16, 2018
Jan. 19, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Equity [Line Items]          
Common stock, shares authorized     500,000,000   500,000,000
Proceeds from Common stock issuance, net of $16,901 issuance costs       $ 3,233,099  
Warrant liability, issuance costs     $ 137,192    
Convertible preferred stock, par value (in dollars per share)     $ 0.001   $ 0.001
Emerald financing issuance costs     $ 154,092    
Reduction to APIC from the issuance of common stock     $ 16,900    
Emerald Health Sciences Inc          
Equity [Line Items]          
Conversion price, per share (in dollars per share)   $ 0.10      
Securities purchase agreement | Emerald Health Sciences Inc          
Equity [Line Items]          
Common stock issued 15,000,000 15,000,000      
Number of warrants issued 20,400,000 20,400,000      
Warrant exercise price $ 0.10 $ 0.10      
Proceeds from Common stock issuance, net of $16,901 issuance costs   $ 1,500,000      
Term of warrants 5 years        
Securities purchase agreement | Emerald Health Sciences Inc | Accredited investor          
Equity [Line Items]          
Common stock issued 2,500,000        
Number of warrants issued 3,400,000        
Warrant exercise price $ 0.10        
Proceeds from Common stock issuance, net of $16,901 issuance costs $ 1,750,000        
Term of warrants 5 years        
Securities purchase agreement | Emerald Health Sciences Inc | Promissory Note          
Equity [Line Items]          
Maximum aggregate gross proceeds   $ 900,000      
Conversion price, per share (in dollars per share)   $ 0.10      
Subsequent financing purchase price, description   The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald Health Sciences shall be issued additional shares in order to protect against anti-dilution.      
Bridge Loan   $ 900,000